October 2022 – Syncromune, Inc.

18Oct

Syncromune, Inc. Enters Into an Exclusive Worldwide License Agreement with Eucure Biopharma Co., LTD., to Develop and Commercialize YH002 (OX40 Anibody) and Two Undisclosed Active Ingredients as Components of the Syncrovax Combination Immunotherapy Platform

Syncromune, Inc. Enters Into an Exclusive Worldwide License Agreement with Eucure Biopharma Co., LTD., to Develop and Commercialize YH002 (OX40 Anibody) and Two Undisclosed Active...